iShares US Pharmaceuticals ETF
149 hedge funds and large institutions have $342M invested in iShares US Pharmaceuticals ETF in 2025 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 32 increasing their positions, 44 reducing their positions, and 7 closing their positions.
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
7% more funds holding
Funds holding: 139 → 149 (+10)
5% more capital invested
Capital invested by funds: $326M → $342M (+$16.8M)
0.52% less ownership
Funds ownership: 58.79% → 58.27% (-0.52%)
27% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 44
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $297K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$932K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$759K |
| 3 |
Rockefeller Capital Management
New York
|
+$736K |
| 4 |
Goldman Sachs
New York
|
+$503K |
| 5 |
Corient Private Wealth
Miami,
Florida
|
+$435K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$6.9M |
| 2 |
Fisher Asset Management
Camas,
Washington
|
-$6.23M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$2.47M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.17M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.91M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
151
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
| – | -$2.47M | -37,636 | Closed |
|
|
BIG
152
Boothe Investment Group
Dover,
Delaware
| – | -$602K | -9,189 | Closed |
|
|
JHCP
153
Jackson Hole Capital Partners
Tulsa,
Oklahoma
| – | -$49.2K | -750 | Closed |
|
|
CA
154
CoreCap Advisors
Southfield,
Michigan
| – | -$6.55K | -100 | Closed |
|
|
GWANC
155
Guardian Wealth Advisors (North Carolina)
Raleigh,
North Carolina
| – | -$5.69K | -87 | Closed |
|
|
TPWA
156
Twin Peaks Wealth Advisors
Burlingame,
California
| – | -$5.63K | -84 | Closed |
|
157
Simplex Trading
Chicago,
Illinois
| – | -$1K | -24 | Closed |
|
IHE Hedge Fund Activity: Q3 2025 in Review
149 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2025, worth a combined $342M — up 5.2% from $326M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new IHE positions and 7 closed out — a net gain of 11 holders — while 32 added to existing stakes and 44 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $932K. The largest seller was BNP Paribas Financial Markets, cutting an estimated $6.9M.
- 149 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2025, up from 139 in Q2 2025.
- Funds reported $342M of iShares US Pharmaceuticals ETF stock for Q3 2025, up 5.2% quarter-over-quarter.
- 18 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2025 and 7 closed out, a net change of +11 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q3 2025 was Jane Street, an estimated $932K added.
- The largest iShares US Pharmaceuticals ETF seller in Q3 2025 was BNP Paribas Financial Markets, an estimated $6.9M sold.
Based on aggregated 13F filings for Q3 2025.